Physician profile
Etienne Schonbach
NPI 1073040580
$5,399.93
in general payments reported to CMS, 2019-2025
20 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,399 · 2022: $1,114 · 2023: $736 · 2024: $743 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,886.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,624.37 | 2021 | |
| Alimera Sciences, INC. | $423.42 | 2021-2024 | Iluvien, Yutiq |
| Alcon Vision LLC | $419.35 | 2024 | Ngenuity, Clareon, Argos |
| Regeneron Pharmaceuticals, INC. | $409.61 | 2023-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $396.08 | 2021-2025 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $321.13 | 2022-2025 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $265.20 | 2023 | Eylea |
| Eyepoint US, INC. | $264.66 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $240.68 | 2022 | |
| Abbvie INC. | $237.40 | 2022-2025 | Lumigan, Ozurdex |
| Glaukos Corporation | $210.49 | 2021-2025 | Photrexa Viscous and Photrexa |
| Allergan, INC. | $124.13 | 2021 | |
| Genentech, INC. | $122.50 | 2022 | |
| Ivantis, INC | $121.27 | 2021 | |
| Ani Pharmaceuticals, INC. | $76.87 | 2023-2025 | Purified Cortrophin Gel, Iluvien, Yutiq |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $48.41 | 2025 | Izervay |
| Ocular Therapeutix, INC. | $37.68 | 2024-2025 | Dextenza |
| Bausch & Lomb Americas INC. | $22.35 | 2022 | |
| Biotissue Holdings INC. | $20.00 | 2024 | |
| Mallinckrodt Hospital Products INC. | $14.33 | 2024 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Etienne Schonbach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.